Genmab — April 2018
-
Prothena’s lead drug has decisively failed a crucial Phase IIb study for rare, second-line cases of AL amyloidosis https://endpts.com/prothenas-lead-drug-neod001-just-imploded-in-2-late-stage-studies-and-theres-nothing-left-to-salvage/ Let's hope Dara will be more successful
-
Som Solsen skriver .. under lav omsætning og shortrobotten kan roligt arbejde videre i sådanne vilkår ... vent til 21 maj, så forventer jeg en kurs i overhalingsbanen ,,,,,,
-
- maj lukket børs ..
-
@ jkj ; the agenda is posted now, no mention of Dara

http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2018/04/WC500247822.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind